Newsroom News At Zentiva, we provide health and wellbeing for all generations Sustainability in Action At Zentiva, sustainability is at the heart of our mission. We’re proud to present the newest episode of Zentiva’s Sustainability Podcast, featuring Mihai Zotta, Conservation Director at Conservation Carpathia Foundation. This episode explores the foundation’s work to restore and protect the Carpathian forests, one of Europe’s most important biodiversity hotspots. Newsroom Newsroom

Sustainability in Action

2025-12-17-sustainability-in-action-rewilding-romanias-forests

Rewilding Romania’s Forests

Newsroom News At Zentiva, we provide health and wellbeing for all generations Zentiva Expands into Biologics with the EU-Wide Launch of Its First Biosimilar Launch marks Zentiva’s strategic entry into biosimilars and reinforces its mission to broaden patient access to high-quality biologic medicines across Europe. Newsroom Prague, 1 December, 2025.  Zentiva, a leading European manufacturer of affordable, high-quality medicines, today announced the first EU-wide launch of a monoclonal antibody biosimilar, following approval by the European Medicines Agency (EMA). This milestone marks Zentiva’s entry into the biosimilar segment, further strengthening its position as a trusted healthcare partner dedicated to improving patient access to essential treatments. The new biosimilar is a monoclonal antibody used in the treatment bone conditions.  Zentiva’s biosimilar has been authorised through the EMA’s centralised procedure and will be made available progressively across European markets starting in December.Zentiva’s entry into biosimilars forms part of its broader strategic growth plan to diversify the company’s product offering beyond traditional generics. With biologic medicines representing a growing share of healthcare spending in Europe, biosimilars are key to ensuring healthcare system sustainability and patient access to modern therapies. Downloads Zentiva Expands into Biologics with the EU-Wide Launch of Its First Biosimilar Zentiva Expands into Biologics with the EU-Wide Launch of Its First Biosimilar Zentiva provides health and wellbeing for all generations, with focus on developing, producing, and delivering high-quality, affordable medicines to more than 100 million people in over 30 countries across Europe and beyond. Zentiva has four wholly-owned manufacturing sites and a broad network of external manufacturing partners to ensure supply security. Zentiva employs more than 5,000 unique talents, bonded together by a commitment to the people who depend on our medicines every day.  Visit us at www.zentiva.com  About Zentiva Media contacts: Newsroom

Zentiva Expands into Biologics with the EU-Wide Launch of Its First Biosimilar

2025-12-01-zentiva-expands-into-biologics

Newsroom News At Zentiva, we provide health and wellbeing for all generations Demonstrating accountability: Zentiva receives prestigious ESG Transparency Award 2025 Newsroom Prague, Czech Republic; 28 November 2025. Zentiva, a leading European generics pharmaceutical company, has received the esteemed ESG Transparency Award 2025 by the EUPD Group. This award recognises companies that excel in clarity, structure and transparency in their Environmental, Social and Governance (ESG) reporting.The awards were presented at the ESG Summit 2025, as part of the European Sustainability Week 2025, hosted by the EUPD Group. The recognition is a testament to the efforts of industry leaders who have embedded sustainability in their business strategy and communicate it transparently according to relevant standards.Zentiva received recognition at the Excellence Level of the ESG Transparency Award 2025 for its high degree of clarity, accessibility and transparency in sustainability reporting. The Excellence Level distinction places Zentiva among the top organisations in Europe in terms of transparent reporting of its ESG disclosures.The company excelled in the presentation of a well-structured and strategically grounded sustainability approach that incorporates current European requirements into governance and reporting processes. Furthermore, the disclosure of climate related information, including the use of renewable electricity at European production sites and its integration into a broader long term climate strategy reached a high level of transparency. In addition, Zentiva offered a full calculation of the indirect carbon footprint with externally reviewed methodology to strengthen data integrity and clearly explained its governance structures, highlighting the role of the Audit Committee in approving sustainability related plans. These results underline the determination of Zentiva to strive to drive positive change for society and the environment.Steffen Klink, COO of the EUPD Group commented: “We proudly congratulate Zentiva on its exceptional commitment to transparent ESG communication, clearly demonstrating accountability by publicly detailing material impacts, risks, and opportunities across key environmental, social, and governance areas. This dedication to holistic performance, including ambitious decarbonization targets and robust global policies on ethical conduct and responsible sourcing, sets a definitive benchmark for industry excellence.” Downloads Demonstrating accountability: Zentiva receives prestigious ESG Transparency Award 2025 Demonstrating accountability: Zentiva receives prestigious ESG Transparency Award 2025 Zentiva provides health and wellbeing for all generations, with focus on developing, producing, and delivering high-quality, affordable medicines to more than 100 million people in over 30 countries across Europe and beyond. Zentiva has four wholly-owned manufacturing sites and a broad network of external manufacturing partners to ensure supply security. Zentiva employs more than 5,000 unique talents, bonded together by a commitment to the people who depend on our medicines every day.  Visit us at www.zentiva.com  About Zentiva Since its foundation in 2000, the EUPD Group has been developing innovative, integrated solutions for sustainability-oriented companies. We lead companies to success with our data-based market research and consulting services in the areas of energy, social and ESG. On the one hand, we have specialised in technology sectors such as photovoltaics, energy storage, heat pumps and electromobility under the topic of “Energy”. In the “Social” category, we also offer services in areas such as occupational health management and equal opportunities, while “ESG” focuses on corporate sustainability and responsibility issues, including their transparency in reporting. Our aim is to help companies become and remain competitive, create optimal framework conditions and develop business opportunities.  www.eupd-group.com   About the EUPD Group The ESG TRANSPARENCY AWARD honours European organisations that have already anchored forward-looking sustainability concepts in their company and communicate these transparently in the form of a sustainability report. These pioneers serve as role models because they change the world and prove that profitability and sustainability are not opposites, but successful strategies for a future worth living. The EUPD Group has developed the ESG Transparency Evaluation Standard to objectively assess transparency, accountability and structural quality of ESG reporting. It draws on the most relevant European and international guidelines of sustainability reporting and serves as the methodical basis of the ESG Transparency Award.  www.esg-transparency-award.de/en/  About the ESG Transparency Award Media contacts: Newsroom

Demonstrating accountability: Zentiva receives prestigious ESG Transparency Award 2025

2025-11-28-demonstrating-accountability

Validating access

zentiva

daily

Default

News

news

News

Connect with us on social media

Latest news

Sustainability in Action

Zentiva Expands into Biologics with the EU-Wide Launch of Its First Biosimilar

Demonstrating accountability: Zentiva receives prestigious ESG Transparency Award 2025

Media contacts

Explore

Stay tuned

Get in touch